AbbVie Inc. (BVMF:ABBV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 2.72T +25.4% |
| Revenue (ttm) | 333.57B +10.4% |
| Net Income | 32.48B +67.7% |
| EPS | 1.18 +68.5% |
| Shares Out | n/a |
| PE Ratio | 81.29 |
| Forward PE | 19.04 |
| Dividend | 1.47 (1.53%) |
| Ex-Dividend Date | Oct 14, 2026 |
| Volume | 567 |
| Open | 95.50 |
| Previous Close | 95.50 |
| Day's Range | 93.90 - 96.97 |
| 52-Week Range | 58.81 - 97.74 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie reports TEMPLE study meets primary endpoint, publishes results
AbbVie (ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head study evaluated the tolerability, safety and effica...
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks th...
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alon...
AbbVie submits BLA for etentamig to U.S. FDA
AbbVie (ABBV) announced the submission of a Biologics License Application to the U.S. FDA for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager administered intravenously fo...
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings...
Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.
Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide. A STEM-focused workshop in San Antonio will b...
A Worthwhile Exit Strategy
This week could mark something that hasn't happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It's all going to depend on if the share price end...
FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s
AbbVie (ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous induction regimen for Skyrizi for adults with moderately to severely active Crohn’s disease. “Patients now hav...
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the...
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after AbbVie’s (ABBV) Phase 3 INTREPID study ...
AbbVie price target raised to $294 from $258 at Goldman Sachs
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVies lutikizumab met Phase 3 endpoints in hidradenitis…
AbbVie Phase 3 Intrepid trial data ‘underwhelms,’ says RBC Capital
After AbbVie (ABBV) announced topline results from the Phase 3 INTREPID study evaluating lutikizumab in moderate to severe hidradenitis suppurativa, RBC Capital noted that the study met its primary en...
AbbVie reports ‘positive’ results from Phase 3 Intrepid trial of lutikizumab
AbbVie (ABBV) announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin 1alpha/1beta ant...
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
AbbVie said on Thursday its experimental drug significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study.
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary...
AbbVie price target raised to $294 from $258 at Goldman Sachs
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVie’s recent outperformance reflects attractive valuation, growing confiden...
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its ...
AbbVie reaches agreement with pCPA for Elahere
AbbVie (ABBV) is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance have successfully been completed for Elahere, and that a Letter of Intent has been signed by both…
AbbVie price target raised to $325 from $300 at Barclays
Barclays raised the firm’s price target on AbbVie (ABBV) to $325 from $300 and keeps an Overweight rating on the shares. The firm expects the company to report a broadly…
AbbVie, McLaren Racing announce partnership
AbbVie (ABBV) and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is...
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partn...
AbbVie reports ABBV-466 trial meets primary endpoint
AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopic remission at Week 12 than either monot...
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The trea...
AbbVie announces new, updated data from solid tumor portfolio at ESMO 2026
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO, Congress, taking place October…